Benzinga | Jul 2, 2021 06:31AM EDT

JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $101

JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and raises the price target from $91 to $101.